Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Evaluation of epithelial ovarian, primary peritoneal, or fallopian tube cancer treatment in first recurrance using platinum-based chemothera… Recruiting

2022-501220-14-00 epithelial ovarian, primary peritoneal, or fallopian tu 4 2023-10-17
A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting

2023-504247-13-00 Large cell neuroendocrine carcinoma 4 2023-10-17
A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal … Recruiting

2022-501684-40-00 Head and Neck Squamous Cell Carcinoma, Non-Small-Cell L 3 2023-10-05
A clinical study of ABSK021 in Patients with Tenosynovial Giant Cell Tumor to determine whether the study drug is safe and how well the ant… Recruiting

2023-503245-58-00 Tenosynovial Giant Cell Tumor 5 2023-10-04
A study to learn how safe the study treatment actinium-225-macropa-pelgifatamab (BAY3546828) is, how it affects the body, how it moves into,… Recruiting

2022-502623-22-00 Metastatic castration-resistant prostate cancer 1 2023-09-18
A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors Recruiting

2022-502654-14-00 Endometrial cancer 4 2023-09-11
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Ca… Recruiting

2022-501703-27-00 Advanced or Metastatic Non-Clear Cell Renal Cell Carcin 5 2023-07-05
Phase 1/2 Open Label solid tumour Safety and Tolerability study in Pediatric and Young Adult subjects. Recruiting

2023-506464-14-00 Advanced solid tumors 9 2023-06-29
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of … Recruiting

2023-504254-35-00 Unresectable locally advanced or metastatic solid tumor 7 2023-06-20
A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn… Recruiting

2022-501709-11-00 Isocitrate deshydrogenase1 mutation-positive (IDH1m) ac 5 2023-06-06
Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting

2022-500544-38-00 Advanced Breast Cancer 5 2023-06-05
A Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors Recruiting

2023-510275-64-00 Hepatocellular carcinoma, colorectal cancer, endometria 9 2023-05-31
Phase II Study of daTopotamab-derUXtecan (Dato-DXd; DS-1026a) in triple-negative brEast cancer patients with newly Diagnosed or prOgressing … Recruiting

2024-518819-19-00 triple negative breast cancer 4 2023-05-23
A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Sm… Recruiting

2023-504595-26-00 Non-Small Cell Lung Cancer 4 2023-05-22
A Ph2 Superiority Study with InO Monotherapy vs ALLR3 for Induction Treatment of Childhood HR ALL Recruiting

2023-509810-13-00 Acute Lymphoblastic Leukemia (ALL) 4 2023-05-13
Selective serotonin reuptake inhibition in patients with advanced gastroesophageal cancer receiving immunochemotherapy: a prospective phase … Recruiting

2024-518631-11-00 gastroesophageal cancer 4 2023-04-25
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizum… Recruiting

2023-509335-60-00 Advanced solid tumors including (but not limited to), n 1 2023-02-23
This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting

2023-505277-32-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2023-01-26
A Study of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with R/R PTCL Recruiting

2022-500391-62-00 Subjects with relapsed/refractory peripheral T-cell lym 9 2023-01-19
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in… Recruiting

2022-501152-28-00 Breast Cancer 4 2022-12-21
Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting

2022-502503-30-00 Acute lymphoblastic leukemia 5 2022-12-15
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors Recruiting

2022-500508-23-00 Advanced solid tumors 1 2022-10-28
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Non-Small Cell Lung Cancer with A… Recruiting

2023-508349-42-00 Non-Small Cell Lung Cancer (NSCLC) harboring activating 3 2022-10-18